IMBiologics

At a glance

IMBiologics filed 31 disclosures in the last 12 months, including 9 5% holder and 4 insider. The most recent key filing was on Sep 10.

Revenue for 2025 was ₩11.6B, down 57.9% on 2024. Operating margin was 2.6% against 50.7% a year earlier. Debt was 2% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩7.2B and operating profit of ₩55.1M.

The 2025 annual report lists 41 employees with an average tenure of 1.9 years and average pay of ₩76.2M. Its 7 directors and auditors were paid ₩110.1M each on average. It paid no cash dividend for 2025. 하경식 and related parties held 19.08% at year end.

From the 2025 annual report

Staff: 41 (17 men, 24 women), of whom 0 on fixed-term contracts. Total pay for the year: ₩2.6B. Directors and auditors: 7, paid ₩660.6M in total.

No cash dividend was paid for 2025.

Largest shareholder

하경식 holds 18.84%; with 1 related party the group holds 19.08% of common shares at year end (from 26.38% at the start of the year).

Auditor: 서우회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary